SOURCE: MMIT Analytics, as of 10/29/19
Thursday, October 31, 2019
Amgen last week said it will...
...standardize the lower list price
for its leading PCSK9 inhibitor, Repatha, by the end of 2020. The drug's
previous list price was $14,520, which the manufacturer dropped by 60% to
$5,860 for those paying out of pocket. The change will put the lower list price
in effect for all insurers. For the treatment of atherosclerotic cardiovascular
disease in the pharmacy benefit, Repatha holds preferred status for just 2% of
covered lives, though this grows to 49% with prior authorization and/or step
therapy.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment